TrialJournal of diabetes investigation2017

Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.

Kyeong Seon Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.